mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant.
2019-nCoV Vaccine mRNA-1273
/ immunology
Adult
Aged
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ immunology
COVID-19
/ immunology
Chlorocebus aethiops
Cohort Studies
Female
Humans
Immunization, Secondary
/ methods
Male
Middle Aged
Mutation
Neutralization Tests
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ genetics
Vaccination
/ methods
Vero Cells
Young Adult
B.1.1.529
Omicron
Omicron variant
SARS-CoV-2
antibody
booster dose
live-virus
mRNA vaccines
neutralization assay
vaccine induced immunity
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
15 02 2022
15 02 2022
Historique:
received:
23
12
2021
revised:
12
01
2022
accepted:
20
01
2022
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant emerged in November 2021 and consists of several mutations within the spike. We use serum from mRNA-vaccinated individuals to measure neutralization activity against omicron in a live-virus assay. At 2-4 weeks after a primary series of vaccinations, we observe a 30-fold reduction in neutralizing activity against omicron. Six months after the initial two-vaccine doses, sera from naive vaccinated subjects show no neutralizing activity against omicron. In contrast, COVID-19-recovered individuals 6 months after receiving the primary series of vaccinations show a 22-fold reduction, with the majority of the subjects retaining neutralizing antibody responses. In naive individuals following a booster shot (third dose), we observe a 14-fold reduction in neutralizing activity against omicron, and over 90% of subjects show neutralizing activity. These findings show that a third dose is required to provide robust neutralizing antibody responses against the omicron variant.
Identifiants
pubmed: 35233550
doi: 10.1016/j.xcrm.2022.100529
pii: S2666-3791(22)00029-5
pmc: PMC8784612
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100529Subventions
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00017
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260563
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400004C
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022.
Déclaration de conflit d'intérêts
M.S.S. serves on the advisory board for Moderna and Ocugen.
Références
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734
pubmed: 34914670
N Engl J Med. 2021 Aug 12;385(7):664-666
pubmed: 34233096
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Med. 2022 Jan 14;3(1):25-27
pubmed: 35590141
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356